The immunophenoscore (IPS) can be used to predict patient immunotherapy responsiveness23, and CRC patients in the low-MRS group exhibited significantly better IPS scores for both PD-1 and combination PD-1 + CTLA4 targeted immunotherapeutic treatment (Fig. 5I–L). This evidence concerns the gene CTLA4 and colorectal carcinoma.